MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China Life Science
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies Life Science
Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody Life Science
Ocumension Signs $13.5 Million Deal for China Rights to Nicox Anti-Inflammatory Eye Drug Life Science